Cat. No.: HY-N0163

Magnolol

Name: Magnolol
Brand: MedChemExpress
SKU: HY-N0163
Price: 32.00 USD
Availability: InStock
Rating: 5 (9 reviews)

9 Cited Publications

Avis client

Based on 9 publication(s) in Google Scholar

Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC₅₀ values of 10.4 µM and 17.7 µM, respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.84%
CAS No.: 528-43-8
Formule: C₁₈H₁₈O₂
Masse moléculaire:266.33

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Magnolol Chemical Structure

CAS No.: 528-43-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (9)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC₅₀ values of 10.4 µM and 17.7 µM, respectively.

IC₅₀ & Target^[1]

PPARγ

17.7 μM (EC₅₀)

Voir tous les produits spécifiques à Isoform RAR/RXR :

Voir tous les produits spécifiques à Isoform PPAR :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
A549	IC₅₀	>5 μg/mL Compound: 5	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17918910]
A549	IC₅₀	>80 μM Compound: MAG	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32044229]
A549	IC₅₀	>80 μM Compound: Magnolol	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 32791403]
A549	IC₅₀	57.36 μM Compound: 12; ML	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30006164]
A549	IC₅₀	82.4 μM Compound: Magnolol	Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33069436]
AGS	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
BV-2	IC₅₀	14.9 μg/mL Compound: 9	Inhibition of NADPH oxidase-mediated ROS production in LPS-stimulated mouse BV2 cells after 20 mins by flow cytometry Inhibition of NADPH oxidase-mediated ROS production in LPS-stimulated mouse BV2 cells after 20 mins by flow cytometry	[PMID: 19086868]
CCRF-CEM	CC₅₀	99.5 μM Compound: 2, magnolol	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 16722664]
CCRF-CEM	IC₅₀	99.5 μM Compound: 1	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 17587572]
CHO	EC₅₀	18.3 μM Compound: 3	Partial agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940 Partial agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940	[PMID: 24900561]
CHO	EC₅₀	3.28 μM Compound: 3	Partial agonist activity at recombinant human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940 Partial agonist activity at recombinant human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940	[PMID: 24900561]
HCC827	IC₅₀	>40 μM Compound: 12; ML	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	[PMID: 30006164]
HCC827	IC₅₀	94.65 μM Compound: Magnolol	Antiproliferative activity against human HCC827 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33069436]
HEK293	IC₅₀	>80 μM Compound: Magnolol	Antiproliferative activity against human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 32791403]
HeLa	IC₅₀	>5 μg/mL Compound: 5	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 17918910]
HeLa	IC₅₀	>80 μM Compound: Magnolol	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 32791403]
HepG2	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
HepG2	IC₅₀	32 μM Compound: 1	Cytotoxicity of compound against human liver tumor cell line (Hep-G2) was determined Cytotoxicity of compound against human liver tumor cell line (Hep-G2) was determined	[PMID: 15582432]
HepG2 2.2.15	CC₅₀	63.68 μM Compound: 5	Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay	[PMID: 23434030]
HepG2 2.2.15	IC₅₀	2.03 μM Compound: 5	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA	[PMID: 23434030]
HepG2 2.2.15	IC₅₀	3.76 μM Compound: 5	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA	[PMID: 23434030]
HepG2 2.2.15	IC₅₀	8.67 μM Compound: 5	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis	[PMID: 23434030]
HL-60	IC₅₀	48 μM Compound: 1	Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay	[PMID: 22424614]
HONE1 cell line	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
K562	IC₅₀	>5 μg/mL Compound: 5	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 17918910]
L02	IC₅₀	>80 μM Compound: Magnolol	Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 32791403]
LoVo	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MCF7	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MCF7	IC₅₀	>80 μM Compound: Magnolol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 32791403]
MDA-MB-231	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MOLT-4	IC₅₀	58 μM Compound: 1	Antiproliferative activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay	[PMID: 22424614]
NCI-H1299	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1650	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1650	IC₅₀	56.65 μM Compound: 12; ML	Antiproliferative activity against human NCI-H1650 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H1650	IC₅₀	66.3 μM Compound: Magnolol	Antiproliferative activity against human NCI-H1650 cells expressing EGFR mutant assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells expressing EGFR mutant assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33069436]
NCI-H1975	IC₅₀	>40 μM Compound: 12; ML	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H1975	IC₅₀	87.28 μM Compound: Magnolol	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33069436]
NCI-H358	IC₅₀	61.23 μM Compound: 12; ML	Antiproliferative activity against human NCI-H358 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H358 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H441	IC₅₀	58.68 μM Compound: 12; ML	Antiproliferative activity against human H441 cells after 72 hrs by MTT assay Antiproliferative activity against human H441 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H441	IC₅₀	65.8 μM Compound: Magnolol	Antiproliferative activity against human NCI-H441 cells expressing EGFR mutant assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H441 cells expressing EGFR mutant assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33069436]
NCI-H460	IC₅₀	>40 μM Compound: 12; ML	Antiproliferative activity against human H460 cells after 72 hrs by MTT assay Antiproliferative activity against human H460 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H460	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H460	IC₅₀	>80 μM Compound: MAG	Antiproliferative activity against human H460 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human H460 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32044229]
NCI-H460	IC₅₀	95.57 μM Compound: Magnolol	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33069436]
Oocyte	EC₅₀	36.8 μM Compound: Magnolol	Modulation of GABA Aalpha1beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique Modulation of GABA Aalpha1beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique	[PMID: 21699169]
OVCAR-3	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
PBMC	CC₅₀	38.6 μM Compound: 2, magnolol	Cytotoxicity against human PBM cells Cytotoxicity against human PBM cells	[PMID: 16722664]
PC-3	IC₅₀	62 μM Compound: 1	Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 22424614]
PC-9	IC₅₀	68.98 μM Compound: 12; ML	Antiproliferative activity against human PC9 cells after 72 hrs by MTT assay Antiproliferative activity against human PC9 cells after 72 hrs by MTT assay	[PMID: 30006164]
RAW264.7	IC₅₀	35.4 μM Compound: 7	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay	[PMID: 24963714]
RAW264.7	IC₅₀	38.9 μM Compound: 7	Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA	[PMID: 24963714]
SGC-7901	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
SW480	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
T47D	IC₅₀	69.32 μM Compound: Magnolol	Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 32791403]
U-251	IC₅₀	>45 μM Compound: MAG	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
Vero	CC₅₀	50.6 μM Compound: 2, magnolol	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 16722664]
Vero	CC₅₀	68.3 μM Compound: 19	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
Vero	EC₅₀	3.8 μM Compound: 19	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
Vero	IC₅₀	50.6 μM Compound: 1	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17587572]

In Vitro

Magnolol is a dual agonist of both RXRα and PPARγ, with EC₅₀ values of 10.4 μM and 17.7 μM, respectively. Magnolol (26.2-80 μM) binds to RXRαLBD and PPARγLBD in a dose dependent manner, with K_d values of 45.7 μM and 1.67 μM, respectively. Magnolol (1-20 μM) induces the transcription of PPRE in a dose-dependent manner, but shows no activity on RXRE transcription^[1]. Magnolol (1, 3, 10 μM) enhances adipocyte differentiation of both 3T3-L1 pre-adipocystes and C3H10T1/2 pluripotent stem cells in the presence of insulin. Magnolol (10 μM) upregulates mRNA expression of marker genes for adipocyte differentiation. Magnolol (1, 10 μM) shows an increase in basal and insulin-stimulated glucose uptake in differentiated 3T3-L1 adipocytes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Magnolol (5-15 mg/kg, p.o.) significantly attenuates the phenotypic severity of dextran sulfate sodium (DSS)-induced colitis in mice. Magnolol (10, 15 mg/kg, p.o.) attenuates histopathological changes and myeloperoxidase activity in the colon of DSS-treated mice, decreases DSS-induced high levels of proinflammatory cytokines TNF-α, IL-1β and IL-6 in the colonic tissues. Magnolol (10 mg/kg, p.o.) also reverses abnormality of serum metabolome, and regulates tryptophan metabolic pathway in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 528-43-8
Appearance Solid
Masse moléculaire 266.33
Formule C₁₈H₁₈O₂
Color White to off-white
SMILES

OC1=CC=C(CC=C)C=C1C2=CC(CC=C)=CC=C2O
Structure Classification
- Phenylpropanoids
- Lignans
- Phenols
- Polyphenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All Cell Proliferation/Viability AssayWBIFRT-PCRHistological Imaging/Staining

Sort by:

Journal Impact Factor

Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
PLoS Biol

FOXA3 regulates cholesterol metabolism to compensate for low uptake during the progression of lung adenocarcinoma. [Abstract]

2024 May 28;22(5):e3002621. PMID: 38805565
Neurosci Bull

Compound from Magnolia officinalis Ameliorates White Matter Injury by Promoting Oligodendrocyte Maturation in Chronic Cerebral Ischemia Models. [Abstract]

2023 Oct;39(10):1497-1511. PMID: 37291477
Microb Pathog

Magnolol ameliorates Streptococcus suis serotype 2-induced pulmonary inflammatory injury in mice via inhibition of GSDMD. [Abstract]

2026 Aug:217:108614. PMID: 42251871
Toxicol Appl Pharmacol

Magnolol targets CCND1 to suppress the proliferation of cholangiocarcinoma cells by inhibiting the Akt and STAT3 pathways. [Abstract]

2026 Jan:506:117619. PMID: 41161542
Antivir Ther

Magnolol inhibits viral replication and enhances antiviral immune responses against porcine reproductive and respiratory syndrome virus (PRRSV) in Marc-145 cells. [Abstract]

2025 Jun;30(3):13596535251345953. PMID: 40434182
Toxicol Lett

2026 Jul 2:423:113152. PMID: 42392381
J Nat Med

Magnolol upregulates CHRM1 to attenuate Amyloid-β-triggered neuronal injury through regulating the cAMP/PKA/CREB pathway. [Abstract]

2022 Jan;76(1):188-199. PMID: 34705126
Biomed Pharmacother

Magnolol against enterovirus 71 by targeting Nrf2-SLC7A11-GSH pathway. [Abstract]

2024 Jul:176:116866. PMID: 38876045

Magnolol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Jul:176:116866. [Abstract]

RD and Hela cells were treated with Magnolol or ribavirin for 48 h. Then the cell viability assay was performed. Half-cytotoxic concentrations (CC50) of Magnolol in RD and HeLa cells were 30.91 μM and 32 μM, respectively.

Magnolol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Jul:176:116866. [Abstract]

RD cells were infected with EV71 (MOI = 0.1) for 2 hours, followed by the addition of continuously diluted Magnolol or ribavirin, and cultured at 37°C for 20 hours. The expression level of VP1 protein was detected by Western blotting.

Magnolol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Jul:176:116866. [Abstract]

RD cells were infected with EV71 (MOI = 0.1) for 2 hours, followed by the addition of continuously diluted Magnolol or ribavirin, and cultured at 37°C for 20 hours. The expression level of VP1 protein was detected using immunofluorescence.

Magnolol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Jul:176:116866. [Abstract]

The virus was mixed with Magnolol at 4 °C for 1 h, and the control group was not co-incubated, and then infected RD cells for 1 h at 37 °C. The culture medium was changed. EV71 vRNA levels were detected at 22 h using qPCR.

Magnolol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Jul:176:116866. [Abstract]

Magnolol (40 mg/kg). Hematoxylin-eosin (HE) staining was used to analyze pathological changes and visualize the pathological changes in the tissues.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (375.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7547 mL

18.7737 mL

37.5474 mL

5 mM

0.7509 mL

3.7547 mL

7.5095 mL

10 mM

0.3755 mL

1.8774 mL

3.7547 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Kinase Assay^[1]

Binding affinities of magnolol towards purified RXRαLBD and PPARγLBD are analyzed using Biacore 3000 instrument. Proteins are covalently immobilized to CM5 chip using a standard amine-coupling procedure in 10 mM sodium acetate buffer (pH 4.2). The chip is equilibrated with a continuous flow of running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20) for 2 hours. Subsequently, magnolol in a gradient of concentrations are injected into the channels at a flow rate of 20 µL/min for 60 seconds, followed by disassociation for 120 seconds. For the coactivator SRC1 recruitment assays, biotin-labelled SRC1 is immobilized to SA chip. Different concentrations of Magnolol are incubated with 5 µM RXRαLBD or PPARγLBD for 1 hour, and then injected to the channel at a flow rate of 20 µL/min for 60 s, followed by disassociation for 120 s^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

For differentiation of 3T3-L1 pre-adipocytes, at 2 days after confluence (defined as day 0), cells are incubated in differentiation medium containing 0.5 mM IBMX, 10 μg/mL insulin and 0.25 μM DEX in DMEM containing 10% fetal bovine serum (FBS). After 2 days, the cell culture medium is changed to DMEM containing 10 μg/mL insulin and 10% FBS. The medium is replaced again with fresh DMEM containing 10% FBS after 2 days. Adipocytes are used 6-8 days after the initiation of differentiation. In adipogenesis studies, 3T3-L1 pre-adipocytes and C3H10T1/2 pluripotent stem cells grown in DMEM supplemented with 10% bovine calf serum (day 0) are treated with insulin (1 μg/mL) with/without Magnolol in 10% FBS contained DMEM at the indicated concentration for 9 days. Fresh medium containing insulin (1 μg/mL) and 10% FBS with/without magnolol is replenished every 3 days^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Experimental colitis mice model is induced by routine administration of dextran sulfate sodium (DSS) solution dissolved in drinking distilled water at a concentration of 2.0% (w/v) ad libitum for 5 consecutive days. Distilled water is given to mice in the normal group for the same period. The body weight of each mice is recorded daily in the morning (9:00 a.m.). On day 6, the mice with significant body weight loss, diarrhea, and gross bleeding are considered as experimental candidates of colitis. All the mice with comparable disease index are then randomly divided into 5 groups (n = 8/group): (1) DSS model group, intragastric administrated with saline; (2) positive control group, intraperitoneal injected with infliximab (5 mg/kg); (3) low dose treatment group, intragastric administrated with Magnolol (5 mg/kg); (4) medium dose treatment group, intragastric administrated with Magnolol (10 mg/kg); (5) high dose treatment group, intragastric administrated with Magnolol (15 mg/kg). The mice in control group receives drinking water without DSS throughout the entire experimental period and intragastric administrated with saline^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (279 KB)
SDS (923 KB)
- English - EN (923 KB)
- Français - FR (923 KB)
- Deutsch - DE (923 KB)
- Norwegian - NO (923 KB)
- Español - ES (923 KB)
- Swedish - SV (923 KB)
- Italian - IT (923 KB)
- Korean - KR (923 KB)
- Portuguese - PT (923 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zhang H, et al. Molecular determinants of magnolol targeting both RXRα and PPARγ. PLoS One. 2011;6(11):e28253. [Content Brief]

[2]. Choi SS, et al. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Life Sci. 2009 Jun 19;84(25-26):908-14. [Content Brief]

[3]. Zhao L, et al. Magnolol, a Natural Polyphenol, Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice. Molecules. 2017 Jul 20;22(7). pii: E1218. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7547 mL	18.7737 mL	37.5474 mL	93.8685 mL
	5 mM	0.7509 mL	3.7547 mL	7.5095 mL	18.7737 mL
	10 mM	0.3755 mL	1.8774 mL	3.7547 mL	9.3869 mL
	15 mM	0.2503 mL	1.2516 mL	2.5032 mL	6.2579 mL
	20 mM	0.1877 mL	0.9387 mL	1.8774 mL	4.6934 mL
	25 mM	0.1502 mL	0.7509 mL	1.5019 mL	3.7547 mL
	30 mM	0.1252 mL	0.6258 mL	1.2516 mL	3.1290 mL
	40 mM	0.0939 mL	0.4693 mL	0.9387 mL	2.3467 mL
	50 mM	0.0751 mL	0.3755 mL	0.7509 mL	1.8774 mL
	60 mM	0.0626 mL	0.3129 mL	0.6258 mL	1.5645 mL
	80 mM	0.0469 mL	0.2347 mL	0.4693 mL	1.1734 mL
	100 mM	0.0375 mL	0.1877 mL	0.3755 mL	0.9387 mL

Bioz

Keywords

Magnolol

9 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Magnolol

Honokiol

Curcumin

Naringenin

Formononetin

Sorafenib

Luteolin

Genistein

Quercetin

Sulforaphane

Docosahexaenoic acid

Baicalin

Regorafenib

Publications Citing Use of MedChemExpress (MCE) Magnolol

Voir tous les produits spécifiques à Isoform RAR/RXR

Voir tous les produits spécifiques à Isoform PPAR

Activité biologique

Chemical Information

Publications (9)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Magnolol

Honokiol

Curcumin

Naringenin

Formononetin

Sorafenib

Luteolin

Genistein

Quercetin

Sulforaphane

Docosahexaenoic acid

Baicalin

Regorafenib

Publications Citing Use of MedChemExpress (MCE) Magnolol

Voir tous les produits spécifiques à Isoform RAR/RXR

Voir tous les produits spécifiques à Isoform PPAR

Activité biologique

Chemical Information

Publications (9)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Magnolol Related Classifications

HY-N0163 Related Classifications

Bioz